1. Background {#s0005}
=============

Human rhinoviruses (HRVs) account for the majority of upper respiratory tract infections (URTI) in all age groups ([@bb0095]). Although recent advances in molecular diagnostic tools have improved our understanding of the impact of HRV infections, they have also revealed confounding factors such as the detection of multiple pathogens and the significance of detecting virus in asymptomatic individuals. As a result, the burden of HRV infections may be overestimated in certain populations ([@bb0065]).

Few studies have investigated asymptomatic HRV infections prior to the implementation of PCR and other molecular diagnostic techniques. Surveillance of 15 children ages 1--9 years over a 12-month period identified 20% of children with asymptomatic HRV infections over 1 year ([@bb0115], [@bb0015], [@bb0040]). In children 3 months to 15 years old, incidence of symptomatic HRV was 6 infections per year ([@bb0155]). The incidence of asymptomatic HRV has not been reported in adult populations; however, the incidence of symptomatic HRV is estimated to be 2--3 infections per person per year ([@bb0100]). Rates of asymptomatic HRV have varied in the literature, and direct comparisons are difficult because of differences in the study population (most populations observed are children), in the definition of an asymptomatic episode, and in the detection method utilized ([@bb0050], [@bb0055], [@bb0070], [@bb0095], [@bb0110], [@bb0115], [@bb0145], [@bb0155]). We sought to detect and characterize asymptomatic and symptomatic HRVs in a cohort of university students enrolled in a clinical trial of vitamin D.

2. Study design {#s0010}
===============

2.1. Study population {#s0015}
---------------------

Of 600 McMaster University undergraduate students participating in a randomized controlled trial of vitamin D and gargling (McFlu2 COLD3), 471 (78.5%) completed all weekly surveys discussing URTI symptoms, 86 (14.3%) completed at least 1 but not all, and 43 (7.2%) completed none ([@bb0025]). The median age of participants was 19 years (interquartile range 18--20 years); 64% were female ([@bb0025]). Participants who submitted at least 1 self-collected nasal swab were included in the current laboratory-based study (n = 502). Participants were followed from weeks 36--43 of 2010 (n = 250) or weeks 36--43 of 2011 (n = 252). Study participants self-collected a mid-turbinate flocked nasal swab (FLOQSwabs; Copan Italia, Brescia, Italy) in CyMol™ transport media (Copan Italia) once weekly -- regardless of symptomatic status -- for a total of 8 weeks ([@bb0090], [@bb0135]) ([Fig. 1](#f0005){ref-type="fig"} ). This study was approved by the Hamilton Health Sciences/Faculty of Health Sciences Research Ethics Board, McMaster University, Hamilton, ON, Canada, and all subjects gave written informed consent.Fig. 1Flow charts of study design during the McFlu2 COLD3 Prevention Trial, Hamilton, ON, Canada; weeks 36--43 2010 and weeks 36--43 2011.

2.2. Sample collection {#s0020}
----------------------

At the time of randomization, study staff oriented each participant with the components of the nasal swab kit and instructed them on the appropriate procedure to self-administer the nasal swab. Participants also received a step-by-step guide describing the procedure as well as a link to an online instructional video developed for the study for a reference at home. There were also weekly visits between the study staff and participants, which provided further opportunities to answer outstanding questions. The FLOQSwab design (Copan Italia) only permits mid-turbinate sample collection; nasopharyngeal specimens were therefore not collected.

2.3. Outcome measures {#s0025}
---------------------

An episode of symptomatic URTI was determined based on 2 criteria: the participant\'s report of a "cold" together with 2 or more URTI symptoms (i.e., runny/stuffy nose, congestion, cough, sneeze, sore throat, muscle aches, or fever) ([@bb0005], [@bb0075], [@bb0080], [@bb0125], [@bb0130]). Uncertain cases where symptoms were reported and no additional information was provided that attributed the symptoms to another cause were adjudicated by 2 infectious disease clinicians ([@bb0025]). Symptom severity and duration were measured using the 21-item Wisconsin Upper Respiratory Symptom Survey (WURSS-21) ([@bb0005]). [Fig. 1](#f0005){ref-type="fig"} identifies the population size and specimens tested for each population. All day 1 nasal swabs from each unique symptomatic event were assessed for viral etiology.

To screen for asymptomatic HRV, we randomly sampled 10% of the nasal swabs collected from participants who never reported a URTI during the entire 8-week study period. Samples were stratified by week (25/week) for a total of 400 swabs (n = 200 in each of 2010 and 2011). A 10% sampling was selected to ensure adequate precision of estimated infection incidence rates. Samples selected for asymptomatic screens were also adjudicated to confirm asymptomatic status.

2.4. Detection of HRV infection and viral load {#s0030}
----------------------------------------------

FLOQ swabs (Copan Italia) placed in 2 mL of CyMol™ transport media (Copan Italia) were extracted using the easyMAG automated extractor according to the manufacturer\'s instruction (bioMeriéux, Montreal, QC, Canada). Twenty microliters of MS2 bacteriophage was added to each sample prior to extraction as an internal extraction control. Clinical specimens were tested for HRV RNA by reverse transcriptase polymerase chain reaction (RT-PCR) amplification of a 400-bp region of the HRV 5′ untranslated region with an HRV-specific assay ([@bb0035], [@bb0060]); samples were also screened for other respiratory viruses with the xTAG™ RVP assay (Luminex Molecular Diagnostics, Toronto, ON, Canada). Viral load was determined by a previously described assay ([@bb0035]). Samples were tested in triplicate; the average of each sample is used in further analysis.

2.5. Identification of HRV species {#s0035}
----------------------------------

Presumptive identification of HRV species was conducted by sequencing a portion of the VP1 gene ([@bb0085]). Five microliters of amplified nucleic acid was sequenced on the ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) (Mobix, Hamilton, ON, Canada). Genotypic designations were assigned according to threshold divergences of 13%, 12%, and 13% for HRV-A, HRV-B, and HRV-C, respectively ([@bb0105], [@bb0120]).

2.6. Statistical analysis {#s0040}
-------------------------

Group comparisons were performed using the χ^2^ test for categorical variables and the Student\'s *t* test for continuous variables. Multivariable linear regression was used to determine if an association exists between viral load and HRV species/symptomatic status. Results were considered statistically significant with a *P*  \< 0.05. All statistical analyses were conducted using SPSS version 20 (IBM, Chicago, IL, USA).

3. Results {#s0045}
==========

3.1. Incidence of HRV in asymptomatic and symptomatic students {#s0050}
--------------------------------------------------------------

Throughout the study, we tested self-collected nasal swabs from 25 randomly selected asymptomatic students per week, equaling a total of 400 asymptomatic students screened for HRV by RT-PCR. HRV was identified in 33/400 (8.3%) of swabs, enterovirus D68 in 4/400 (1.0%), and coxsackievirus A6 in 1/400 (0.25%). By comparison, there were 165 reported symptomatic events (121 self-reported, 44 adjudicated), for which a viral pathogen was identified in 92 (55.8%) events. HRV was the predominant pathogen identified (85/92; 92.4%), followed by enterovirus D68 (7/92; 7.6%), and coronavirus NL63 (1/92; 1.1%).

We compared the distribution of HRV infections in the participants. Peak asymptomatic infections occurred in weeks 37 and 38 in 2010 and 2011, respectively ([Fig. 2](#f0010){ref-type="fig"} ). Peak symptomatic infections occurred a week after. The incidence rates of asymptomatic and symptomatic presentation were calculated as 8.3%/week and 1.9%/week, respectively. These rates were determined by inferring that the same proportion of events occurred in the entire asymptomatic population. The start of an asymptomatic infection was determined by testing the sample given the week before.Fig. 2Weekly positivity rate of asymptomatic and symptomatic HRV in weeks 36--43 in 2010 and 2011. The percent positivity of HRV infections by week in 2010 (a) and 2011 (b) in university students. The percentage of positive asymptomatic HRV each week is determined by the number of HRVs identified in the 10% weekly random sampling (n = 25/week in 2010 and n = 25/week in 2011). The percentage of positive symptomatic HRV was determined by the number of positive HRV identified in the student population each week (n = 250/week in 2010 and n = 252/week in 2011).

3.2. Comparison of HRV species in asymptomatic and symptomatic students {#s0055}
-----------------------------------------------------------------------

A portion of the VP1 gene of HRV positives was sequenced to determine species. Of the 118 HRV-positive specimens (33 asymptomatic and 85 symptomatic), 113 (95.7%) were sequenced, and 5 had unresolved sequences (4.2%). HRV-A and HRV-B were the most common species among the participants in both the asymptomatic and symptomatic students ([Table 1](#t0005){ref-type="table"} ). There was no significant difference in HRV-C distribution (*P*  = 0.37).Table 1Distribution of HRV-A, HRV-B, and HRV-C in asymptomatic and symptomatic students.[a](#tf0005){ref-type="table-fn"}A (%)B (%)[b](#tf0010){ref-type="table-fn"}C (%)[c](#tf0015){ref-type="table-fn"}TotalAsymptomatic15 (48.4)14 (45.1)2 (6.5)31Symptomatic39 (47.6)34 (41.4)9 (12.3)82[^1][^2][^3]

3.3. Comparison of HRV viral loads in asymptomatic and symptomatic students {#s0060}
---------------------------------------------------------------------------

We sought to determine whether a difference in viral load could account for the presence or absence of symptoms. The mean viral load (±SD) of HRV in 33 asymptomatic students was 5.3 (±1.5) log~10~ copies/mL versus 6.4 (±1.3) log~10~ copies/mL in 85 symptomatic students. The mean difference was 1.2 log~10~ copies/mL (95% confidence interval \[CI\] 0.59--1.72; *P*  \< 0.001) ([Fig. 3](#f0015){ref-type="fig"} ). Viral load was higher in the presence of symptoms (β = 0.92; *P*  = 0.004), adjusting for HRV species. However, HRV species was not associated with increased viral load (β = −0.39; *P*  = 0.37).Fig. 3Box and whiskers plot of HRV viral loads (log~10~ copies/mL) in asymptomatic (n = 33) and symptomatic (n = 85) university students. The solid line represents the median; the bottom and top of the box represent 25th and 75th percentiles, and the whiskers represent the minimum and maximum data points, respectively. Mean difference in viral load was 1.2 log~10~ copies/mL (95% CI 0.59--1.72; *P* \< 0.001).

3.4. Duration of infection in asymptomatic and symptomatic students {#s0065}
-------------------------------------------------------------------

We investigated the duration of asymptomatic HRV episodes by testing swabs provided by HRV-positive asymptomatic students a week before and a week after the PCR positive was first identified. Of the 33 asymptomatic individuals, 10 (30.3%) were positive 1 week later, which indicates a period of at least 8 days of infection. We sequenced a portion of the VP1 gene of HRV in those individuals on days 1 and 8 to determine if the same genotype or a novel genotype was present on day 8. We identified 4/10 (40.0%) with the same genotype, and 6/10 (60.0%) were infected with a new genotype. An electronic symptom diary was sent to the 106 students who reported a symptomatic URTI, of whom 69 (65.1%) completed the diary in full. From the students who completed the diary, the mean duration of symptoms (±SD) was 6.1 (±1.1) days.

4. Discussion {#s0070}
=============

In this study, we characterized asymptomatic and symptomatic HRV infections in 2 cohorts of university students. HRV incidence rates were calculated to be 8.3%/week and 1.9%/week for asymptomatic and symptomatic students, respectively. To our knowledge, our study is the first to determine the incidence of asymptomatic HRV infection in an adult population. In cases of symptomatic HRV, incidence has been documented at 1.6 colds/9 months per student ([@bb0015], [@bb0120]). The weekly distributions of HRV illustrated that asymptomatic HRV peaked just prior to the symptomatic infections. This suggests that there is a relationship between the incidence of asymptomatic infections and the spread of symptomatic illness in the community.

Partial sequencing of the VP1 gene determined that the distribution of HRV species was similar in both populations, indicating that species may not account for the presence or absence of symptoms. A larger study would be necessary to confirm this finding as we only identified 11 episodes of HRV-C (2 asymptomatic and 9 symptomatic) in our student cohorts. Interestingly, when we investigated a cohort of hospitalized children with respiratory illness during the same time frame, we identified a higher proportion of HRV-C ([@bb0030]). The lower number of HRV-Cs identified in our student cohort may indicate that HRV-C infections are more common in children than in healthy adults, as previously suggested by [@bb0010]. In our study, HRV-B was identified at a higher frequency than has been previously reported ([@bb0150], [@bb0140]). In 271 adults presenting with URTI, 25% were infected with HRV-B and HRV-C and had a lower percentage of URTI symptoms compared to HRV-A (χ^2^  = 7.18; *P*  \< 0.05) ([@bb0140]). This indicates that HRV-B may be associated with mild or asymptomatic infection in adults.

We found that the viral load in asymptomatic students was an average of 1.2 log~10~ copies/mL (*P*  \< 0.001) lower than in symptomatic students as has been documented by [@bb0045] in asymptomatic children. Viral loads of 4.5--5.0 log~10~ copies/mL or greater have been previously observed in symptomatic children ages 1--6 infected with HRV ([@bb0020], [@bb0045]). In our study, we could not conclusively distinguish whether a person was asymptomatic or symptomatic by viral load alone. There are likely differences in the level of acquired immunity in different age groups, and research involving HRV viral loads in previously exposed individuals is required ([@bb0115]).

Our study design allowed us to crudely estimate the duration of virus shedding in asymptomatic students by examining weekly swabs; however, we were unable to accurately identify the true start of an infection. In 4 individuals, the same HRV episode was identified 8 days later, consistent with reports stating that HRV infections do not persist beyond day 11 ([@bb0040], [@bb0055]). This also agrees with our previous study of symptomatic university students, who self-sampled 7 times during the first 14 days of their illness. In that study, we found that HRV RNA persisted in a symptomatic individual for 7--12 days with no change in genotype ([@bb0035]). Our current observations indicate that asymptomatic HRV RNA was present for a similar length of time.

There are limitations to our study design that need to be taken into account. In 73 symptomatic events, a viral etiology could not be identified; this could be accounted for by symptoms confused for allergic events or a viral pathogen that could not be detected by the xTAG™ RVP assay. Our study period only looked at September and October when HRV is most frequently detected in North America. To accurately estimate the annual rate of asymptomatic HRV incidence, surveillance throughout the year would need to be conducted. We utilized an absolute quantitation method to determine the amount of virus. Differences in methodology and imprecision among any quantitative polymerase chain reaction (qPCR) assay make direct comparisons between reports difficult to conduct unless digital qPCR is conducted. While previous studies have shown that self-sampling with flocked nasal swabs has consistent quality, our viral load results should not be directly compared with previous studies ([@bb0135]). The identification of symptoms is subjective, and there is a risk that some students had such minimal symptoms that they did not perceive and report any, whereas others may have low tolerance and would report symptoms. In order to minimize reporting bias, all participants were required to submit self-collected nasal swabs weekly regardless of symptom status as it became a weekly activity. Additionally, during the weekly visits, study staff could confirm that any symptoms were properly recorded.

In summary, we have shown that HRV infections are common in university students, with a similar distribution of species regardless of symptomatic status. HRV-B was commonly identified, and viral load, regardless of species, was lower in asymptomatic students than in those with symptoms. This stresses the importance of taking preventative measures such as handwashing in order to limit the transmission of HRV from person to person and highlights the need for studies investigating the factors, which lead from asymptomatic to symptomatic infections.

[^1]: HRV species determined by partial sequencing of the HRV VP1 gene.

[^2]: Comparison of HRV-B frequency to HRV-A and HRV-C, χ^2^ = 0.064, *P* = 0.80.

[^3]: Comparison of HRV-C frequency to HRV-A and HRV-B, χ^2^ = 0.79, *P* = 0.37.
